Developing Consistent Measures for Cost Analysies of Dementia Behavioral Trials: A Review of Four Study Protocols

Abstract

INTRODUCTION Despite the recent downward trend in the incidence of dementia over the past decades1, 5.4 million Americans live with Alzheimer’s disease and this number is expected to nearly triple by 2050. Behavioral interventions for dementia demonstrate the potential to reduce disease burden and avoid adverse effects associated with pharmacological interventions. To demonstrate the benefits of behavioral interventions for dementia, key stakeholders in healthcare must be aware of the costs of each intervention Economic evaluation of behavioral interventions with respect to specific outcomes is crucial because it allows for comparison to usual care and/or other treatments. There is a need to standardize the collection of health economic measures in clinical trials evaluating non-pharmacologic interventions for dementia patients. OBJECTIVE To develop the Dementia Behavioral Intervention Cost and Outcomes Planner (DBI-COP), a tool to guide investigators in collecting health economic data when evaluating dementia behavioral interventions.

Publication
Poster presentation at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Date